NewAmsterdam Pharma vs Tenax Therapeutics
NAMS and TENX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NAMS | TENX |
|---|---|---|
| Size and price | ||
| Market cap | – | $60.6M |
| Share price | $20.14 | $1.62 |
| Change, 1 year | −47.4% | −76.8% |
| Change, 5 years | 105% | −99.9% |
| Beta (5Y) | 0.83 | 0.62 |
| Employees | 100 | 14 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.6× |
| Growth | ||
| Revenue growth (TTM) | −26.4% | – |
| Profitability | ||
| Operating margin | −900% | – |
| Net margin | −790% | – |
| FCF margin | −582% | – |
| Return on equity | −30.2% (better) | −64.2% |
| Return on invested capital | −1333% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.76 | 14.01 (better) |
| Altman Z-score | – | −1.49 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 81.1% |
| Held by insiders | 22.0% | 4.8% |
| Insider net buying, 12 months | −$63.0M | $6.5M (better) |
| Short interest, % of float | – | 16.3% |
Go deeper
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
- TENX stock overview
- TENX income statement
- TENX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.